Engineering For Impact: A Conversation With Mike Dybicz On The HV3 And Safepak Systems

When it comes to cell and gene therapy (CGT), the margin for error is incredibly small. Lives depend on flawless execution every time. That’s why Cryoport Systems is investing in more than just logistics; they’re engineering peace of mind. In this exclusive interview, Mike Dybicz, Senior Vice President and Chief Product Development Officer, shares how innovations—the Cryoport Express Cryogenic HV3 Shipping System and the Safepak System 1800—are setting new industry standards.

The HV3 system addresses major logistical challenges, including flight availability and handling limitations, by optimizing shipper design for mobility, cargo acceptance, and tamper resistance. Meanwhile, the Safepak System addresses a critical yet often overlooked issue: blood bag breakage, by eliminating metal-on-metal contact and utilizing shock-absorbing, cryogenic-friendly materials. Together, these systems exemplify Cryoport Systems’ mission to place the patient at the center of every design decision, which ensures that each therapy arrives safely and securely.  Explore the ways these systems are transforming CGT logistics.